Tagged with

France Professor Jean-Yves Blay stands as a distinguished figure in contemporary oncology, serving simultaneously as a practising medical oncologist, cancer researcher, and institutional leader. Currently director general of a comprehensive cancer centre and president of the French Federation of Comprehensive Cancer Centres, he has also held pivotal roles, including Director of…

China This week’s China biopharma roundup from PharmaBoardroom content partner Selesta covers Legend Biotech’s planned secondary listing, Betta’s Hong Kong IPO move, iRegene’s USD 40mn raise after FDA Fast Track for its Parkinson’s cell therapy, and Rapafusyn’s USD 44mn Series A for molecular glues. On the clinical front, Junshi posts positive…

APAC Asia Pacific bears the world’s heaviest burden of vision loss, accounting for two-thirds of all moderate-to-severe impairment. With ageing populations and rising diabetes prevalence driving the trend, millions face preventable blindness despite most cases being manageable through early detection and treatment. Against this backdrop, Ahmed Elhusseiny, Area Head for Roche…

MEA The Middle East and Africa (MEA) pharmaceutical market is booming. According to IQVIA, the market reached USD 32.6 billion in value last year with value sales growth at 10.5 percent versus the previous year. Saudi Arabia, the largest market in MEA at USD 11.6 billion in value, expanded at 9.1…

UK Writing in the September 2025 edition of DIA’s Global Forum magazine, Janet Messer, Catherine Blewett, and Naho Yamazaki of the UK Health Research Authority (HRA) and Stephen Lam, Crina Cacou, Anthony Carter, and Sara Rajendran of the UK Medicines and Healthcare products Regulatory Agency (MHRA), lay out how UK clinical…

Japan Writing in the September 2025 edition of DIA’s Global Forum magazine, Seiko Usami, Shinichi Noda, Daisuke Koga, and Naoyuki Yasuda of the Pharmaceuticals and Medical Devices Agency (PMDA), Japan’s regulatory body, outline the benefits for global pharma of including Japan in their drug development activities.   Japan is one of…

France Virginie Beaumeunier, head of France’s CEPS, brings deep expertise in competition law and economic regulation to pharmaceutical pricing. Her background—including roles at the Finance Inspectorate and Competition Authority—shapes her approach to balancing innovation, cost control, and industrial sovereignty. This interview highlights France’s evolving regulatory landscape, marked by a shift toward…

USA The latest stories from healthcare and the life sciences in the US. RFK Jr shares his 128 recommendations for addressing childhood chronic disease; Suspension of Capsida’s gene therapy clinical trial after patient death; Courts half another attempt to challenge the IRA’s negation program; Takeda scoops up former Lilly exec to…

USA Jake Becraft, Co-founder and CEO of Strand Therapeutics, explains their innovative autonomous medicine platform that targets gene expression for precise cell-specific genetic therapies. Focusing initially on cancers like melanoma and breast cancer, the company aims to overcome current therapy limitations and build a fully integrated biotech, while tackling industry challenges…

argenx Carl-Michael Simon, Country Manager for Mid-Size Markets at argenx, discusses how the company has grown from its Dutch and Belgian origins into a global biotech delivering precision medicines for autoimmune diseases. From the landmark approval of VYVGART to new formulations, market access strategies, and the ambitious goal of reaching 50,000…

Switzerland Dr. Dragan Grabulovski, CEO and co-founder of Araris, shared how his journey from co-founding Covagen to advising venture firms shaped his vision for building a platform-driven biotech company. He explained how Araris’s proprietary conjugation technology solves key limitations in ADC development, including enabling multi-payload approaches for greater efficacy. “Our vision…

USA Marwan Fathallah, President and CEO of DIA, outlines how the organisation has evolved into a neutral platform bringing together regulators, industry, and academia to navigate the most pressing issues in healthcare and life sciences. From the transformative potential of AI to the realities of drug pricing, onshoring, and global competition,…